1. Cao X, Gibbs S, Fang L, et al. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res. 2006;23(8):1675-1686.
2. Chiou W, Barve A. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res. 1998;15(11):1792 -1795.
3. Zhao Y, Abraham M, Le J, et al. Evaluation of rat intestinal absorption data and correlation with human intestinal absorption. Eur J Med Chem. 2003;38(3):233 -243.
4. Kadono K, Koakutsu A, Naritomi Y, et al Teramura T. Comparison of intestinal metabolism of CYP3A substrates between rats and humans: application of portal- systemic concentration difference method. Xenobiotica. 2014;44(6):511-521.
5. Zhang Y, Hsieh Y, Izumi T, et al. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague- Dawley rats. J Pharmacol Exp Ther. 1998;287(1):246-252.
6. Humphreys W, Obermeier M, Chong S, et al. Oxidative of acylguanidine prodrugs: intestinal presystemic activation in rats limits absorption and can be inhibited by co- administration of ketoconazole. Xenobiotica. 2003;33(1):93-106.
7. Kotegawa T, Laurijssens B, Von Moltke L, et al. In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J Pharmacol Exp Ther. 2002;302(3):1228-1237.
8. Matsuda Y, Konno Y, Satsukawa M, et al. Assessment of intestinal availability of various drugs in the oral absorption process using portal vein-cannulated rats. Drug Metab Dispos. 2012;40(12):2231-2238.
9. Fukuda K, Ohta T, Oshima Y, et al. Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics. 1997;7(5):391-396.
10. He K, Iyer K, Hayes R, et al. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol. 1998;11(4):252-259.
11. de Castro W, Mertens-Talcott S, Derendorf H, et al. Effect of grapefruit juice, naringin, naringenin, and bergamottin on the intestinal carrier-mediated transport of talinolol in rats. J Agric Food Chem. 2008;56(12):4840-4845.
12. Sugimoto H, Hirabayashi H, Kimura Y, et al. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats. Drug Metab Dispos. 2011;39(1):8-14.
13. Ward K, Azzarano L. Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2- (1,2,3,4-tetrahydro-6,7- dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine- carboxamide) in the mouse, rat, dog, and monkey. J Pharmacol Exp Ther. 2004;310(2):703-709.
14. Su Y, Hu P, Lee S, et al. Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan. J Pharm Pharm Sci. 2007;10(4):519-536.
15. Mitschke D, Reichel A, Fricker G, et al. Characterization of cytochrome P450 protein expression along the entire length of the intestine of male and female rats. Drug Metab Dispos. 2008;36(6):1039-1045.
16. Bailey D, Spence J, Munoz C, et al. Interaction of citrus juices with felodipine and nifedipine. Lancet. 1991;337(8736):268-269.
17. Ducharme M, Warbasse L, Edwards D. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther. 1995;57(5):485-491.
18. Kupferschmidt H, Ha H, Ziegler W, et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther. 1995;58(1):20-28.
19. Kupferschmidt H, Fattinger K, Ha H, et al. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol. 1998;45(4):355- 359.
20. Lilja J, Kivistö K, Backman J, et al. Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther. 1998;64(6):655-660.
21. Lilja J, Kivistö K, Neuvonen P. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther. 2000;68(4):384-390.
22. Rioux N, Bellavance E, Bourg S, et al. Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model. Biopharm Drug Dispos. 2013;34(7):396-401.
23. Cvetkovic M, Leake B, Fromm M, et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999;27(8).
24. Kamath A, Yao M, Zhang Y, et al. Effect of fruit juices on the oral bioavailability of fexofenadine in rats. J Pharm Sci. 2005;94(2):233-239.
25. Lilja J, Kivistö K, Backman J, et al. Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther. 1998;64(6):655-660.
26. Kenny JR, Grime K. Pharmacokinetic consequences of time-dependent inhibition using the isolated perfused rat liver model. Xenobiotica. 2006;36(5):351-365.
27. Wang EJ, Casciano CN, Clement RP, et al. Inhibition of P-glycoprotein transport function by grapefruit juice psoralen. Pharm Res. 2001;18(4):432-438.
28. Bedada S, Sudhakar Y, Neerati P. Resveratrol enhances the bioavailability of fexofenadine in healthy human male volunteers: involvement of P-glycoprotein inhibition. Bioequivalence Bioavailab. 2014;6(5):158-163.
29. Misaka S, Miyazaki N, Yatabe M, et al. Pharmacokinetic and pharmacodynamic interaction of nadolol with itraconazole, rifampicin and grapefruit juice in healthy volunteers. J Clin Pharmacol. 2013;53(7):738-745.
30. Miyazaki N, Misaka S, Ogata H, et al. Effects of itraconazole, dexamethasone and naringin on the pharmacokinetics of nadolol in rats. Drug Metab Pharmacokinet. 2013;28(4):356-361.
31. Bedada S, Yellu N, Neerati P. Effect of resveratrol on the pharmacokinetics of fexofenadine in rats: Involvement of P-glycoprotein inhibition. Pharmacol Rep. 2016;68(2):338-343.
32. Amidon GL, Sinko PJ, Fleisher D. Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm Res. 1988;5(10):651-654.
33. Varma MVS, Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E- TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci. 2005;25(4-5):445-453.
34. Tamura S, Ohike A, Ibuki R, et al. Tacrolimus is a class II low-solubility highpermeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. Pharm Sci. 2002;91(3):719-729.
35. Athukuri B, Neerati P. Enhanced oral bioavailability of diltiazem by the influence of gallic acid and ellagic acid in male wistar rats: involvement of CYP3A and P-gp Inhibition. Phytother Res. 2017;31(9):1441-1448.
36. Sandström R, Karlsson A, Lennernäs H. The absence of stereoselective P-glycoprotein- mediated transport of R/S-verapamil across the rat jejunum. Pharm Pharmacol. 1998;50(7):729-735.
37. Ho Y, Huang D, Hsueh W, et al. Effects of St. John's wort extract on indinavir pharmacokinetics in rats: differentiation of intestinal and hepatic impacts. Life Sci. 2009;85(7-8):296-302.
38. Dahan A, Amidon G. Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein. Pharm Res. 2009;26(4):883-892.
39. Lévesque J, Bleasby K, Chefson A, et al. Impact of passive permeability and gut efflux transport on the oral bioavailability of novel series of piperidine-based renin inhibitors in rodents. Bioorg Med Chem Lett. 2011;21(18):5547-5551.
40. Liu H, Sun H, Wu Z, et al. P-glycoprotein (P-gp)-mediated efflux limits intestinal absorption of the Hsp90 inhibitor SNX-2112 in rats. Xenobiotica. 2014;44(8):763-768.
41. Yang J, Milton M, Yu S, et al. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Drug Metab Lett. 2010;4(4):201- 212.
42. Liu X, Cheong J, Ding X, et al. Use of cassette dosing approach to examine the effects of Pglycoprotein on the brain and cerebrospinal fluid concentrations in wild-type and P- glycoprotein knockout rats. Drug Metab Dispos. 2014;42(4):482-491.
43. Matsuda Y, Konno Y, Hashimoto T, et al. In vivo assessment of the impact of efflux transporter on oral drug absorption using portal vein-cannulated rats. Drug Metab Dispos. 2013;41(8):1514-1521.
44. Yamamoto S, Kosugi Y, Hirabayashi H, et al. Impact of P-Glycoprotein on intestinal absorption of an Inhibitor of apoptosis protein antagonist in rats: mechanisms of nonlinear pharmacokinetics and food effects. Pharm Res. 2018;35(10):190.
45. Tachibana T, Kato M, Sugiyama Y. Prediction of nonlinear intestinal absorption of CYP3A4 and Pglycoprotein substrates from their in vitro Km values. Pharm Res. 2012;29(3):651-668.
46. Hong S, Chang K, Koh Y, et al. Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P- glycoprotein inhibition by lovastatin. Arch Pharm Res. 2009;32(10):1447-1452.
47. Hong S, Yang J, Han J, et al. Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin. J Pharm Pharmacol.2011;63(1):129-135.
48. Yigitaslan S, Erol K, Cengelli C. The effect of P-Glycoprotein inhibition and activation on the absorption and serum levels of cyclosporine and tacrolimus in rats. Adv Clin Exp Med. 2016;25(2):237-242.
49. Karibe T, Hagihara-Nakagomi R, Abe K, et al. Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRPinhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP Substrates. Pharm Res. 2015;32(5):1634-1647.
50. Gotanda K, Tokumoto T, Hirota T, et al. Sulfasalazine disposition in a subject with 376C>T (Nonsense Mutation) and 421C>A variants in the ABCG2 gene. Br J Clin Pharmacol. 2015;80(5):1236-1237.
51. Yamasaki Y, Ieiri I, Kusuhara H, et al. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin Pharmacol Ther. 2008;84(1):95-103.
52. Wan Z, Wang G, Li T, et al. Marked alteration of rosuvastatin pharmacokinetics in healthy chinese with ABCG2 34G>A and 421C>A homozygote or compound heterozygote. J Pharmacol Exp Ther. 2015;354(3):310-315.
53. Lee H, Hu M, Lui S, et al. Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics. 2013;14(11):1283-1294.
54. Zhang W, Yu B, He Y, et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy chinese males. Clin Chim Acta. 2006;373(1-2):99-103.
55. Keskitalo J, Zolk O, Fromm M, et al. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2009;86(2):197-203.
56. Li R, Barton H. Explaining ethnic variability of transporter substrate pharmacokinetics in healthy asian and caucasian subjects with allele frequencies of OATP1B1 and BCRP: A mechanistic modeling analysis. Clin Pharmacokinet. 2018;57(4):491-503.
57. Soko N, Chimusa E, Masimirembwa C, et al. An African-specific profile of pharmacogene variants for rosuvastatin plasma variability: Limited role for SLCO1B1 c.521T>C and ABCG2 c.421A>C. Pharmacogenomics J. 2019;19(3):240-248.
58. Kunimatsu S, Mizuno T, Fukudo M, et al. Effect of P-glycoprotein and breast cancer resistance protein inhibition on the pharmacokinetics of sunitinib in rats. Drug Metab Dispos 2013;41(8):1592-1597.
59. Matsuda Y, Konno Y, Hashimoto T, et al. In Vivo assessment of the impact of efflux transporter on oral drug absorption using portal vein-cannulated rats. Drug Metab Dispos. 2013;41(8):1514-1521.
60. Zhou X, Zhang F, Chen C, et al. Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites. Xenobiotica. 2017;47(3):267-275.
61. Sun X, Li J, Guo C, et al. Pharmacokinetic effects of curcumin on docetaxel mediated by OATP1B1, OATP1B3 and CYP450s. Drug Metab Pharmacokinet. 2016;31(4):269- 275.
62. Lee C, Ki S, Choi J. Effects of oral curcumin on the pharmacokinetics of intravenous and oral etoposide in rats: Possible role of intestinal CYP3A and P-gp inhibition by curcumin. Biopharm Drug Dispos. 2011;32(4):245-251.
63. Lee CK, Ki SH, Choi JS. Effects of oral curcumin on the pharmacokinetics of intravenous and oral etoposide in rats: possible role of intestinal CYP3A and P-gp inhibition by curcumin. Biopharm Drug Dispos. 2011;32(4):245-251.
64. Karlgren M, Vildhede A, Norinder U, et al. Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012;55(10):4740-4763.
65. Treiber A, Schneiter R, Delahaye S, et al. Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. J Pharmacol Exp Ther. 2004;308(3):1121-1129.
論文の公開元へ
